Skip to main content
. Author manuscript; available in PMC: 2022 Nov 14.
Published in final edited form as: Spine J. 2021 May 21;21(9):1520–1527. doi: 10.1016/j.spinee.2021.05.014

Table 2.

Incidence of any and all cardiometabolic morbidities among adults with and without SCI with one-year clean enrollment period.

†No Outcome at Baseline
Case/Denominator Control/Denominator
Any Cardiometabolic Morbidity 1527/2718 (56.2%)* 328752/904321 (36.4%)
  Cardiac dysrhythmias 2477/7112 (34.8%)* 225021/1365803 (16.5%)
  Heart Failure 1393/8259 (16.9%)* 70573/1444810 (4.9%)
  Peripheral and visceral atherosclerosis 2001/8098 (24.7%)* 113708/1429279 (8.0%)
 Non-Alcoholic Fatty Liver Disease 472/8938 (5.3%)* 52000/1462013 (3.6%)
  Chronic kidney disease 1341/8269 (16.2%)* 90704/1433320 (6.3%)
 Type 2 Diabetes 1115/7032 (15.9%)* 120202/1305982 (9.2%)
  Hypercholesterolemia 1824/7148 (25.5%)* 219222/1300144 (16.9%)
  Hypertension 1636/3741 (43.7%)* 254523/1028251 (24.8%)
*

P<.01 and standard mean difference (SMD) ≥0.2

†

Denominators for both cases and controls reflect a one-year clean period during their enrollment for the specific condition. For instance, among cases (SCI), there exist 7,112 patients whose first year of enrollment had no evidence of Cardiac dysrhythmias; therefore, inferred incident Cardiac dysrhythmias could be estimated for this subset of the full SCI cohort. As a result, all patient cohorts’ denominators dynamically change conditional on the incident outcome being measured to ensure a clean period in the first year of enrollment.